FDA Will Require Additional Long-Term Data For COX-2 Inhibitors

“It’s really premature for us to say right now how our requirements are going to change,” CDER Acting Director Galson says. However, the agency will “ask for more long-term data” for COX-2 inhibitors in the pipeline and those already on the market in the wake of the Vioxx withdrawal.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet